GSK stock catapulted Wednesday after the UK-based drugmaker said it expects sales in five years' time to approach $55 billion ...

GSK plc GSK reported fourth-quarter 2025 core earnings of 68 cents per American depositary share (ADS), which beat the Zacks ...

GSK's RSV vaccine Arexvy has received European Commission approval for use in adults aged 18 and over. The decision expands eligibility beyond the previous focus on adults aged 60+ and those at higher ...

If you are wondering whether GSK shares offer good value right now, you are not alone, especially with the stock firmly back ...

GSK plc reports fourth-quarter earnings Wednesday, marking the first results under new Chief Executive Luke Miels as the ...

New boss Luke Miels knows perils of overpromising but there is growing sense pharma firm is closer to filling potential ...

GSK acquires Rapt Therapeutics for $2.2B. Stock surges 65% as pharma giant gains access to phase 2b food allergy treatment ozureprubart.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

GSK plc (NYSE:GSK) and Spero Therapeutics Inc (NASDAQ:SPRO) on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) ...